NuVasive, Inc. (NUVA): Price and Financial Metrics

NuVasive, Inc. (NUVA): $65.25

0.24 (+0.37%)

POWR Rating

Component Grades














  • Value is the dimension where NUVA ranks best; there it ranks ahead of 88.36% of US stocks.
  • NUVA's strongest trending metric is Growth; it's been moving up over the last 31 weeks.
  • NUVA's current lowest rank is in the Sentiment metric (where it is better than 7.63% of US stocks).

NUVA Stock Summary

  • NUVA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 68.28 -- higher than 68.37% of US-listed equities with positive expected earnings growth.
  • Over the past twelve months, NUVA has reported earnings growth of -99.02%, putting it ahead of merely 20.08% of US stocks in our set.
  • As for revenue growth, note that NUVA's revenue has grown -7.91% over the past 12 months; that beats the revenue growth of 31.44% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Nuvasive Inc are MTW, REVG, MG, CCMP, and CRY.
  • NUVA's SEC filings can be seen here. And to visit Nuvasive Inc's official web site, go to

NUVA Price Target

For more insight on analysts targets of NUVA, see our NUVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $73.50 Average Broker Recommendation 1.79 (Moderate Buy)

NUVA Stock Price Chart Interactive Chart >

Price chart for NUVA

NUVA Price/Volume Stats

Current price $65.25 52-week high $72.61
Prev. close $65.01 52-week low $43.11
Day low $62.97 Volume 321,100
Day high $65.29 Avg. volume 680,311
50-day MA $68.45 Dividend yield N/A
200-day MA $57.58 Market Cap 3.37B

NuVasive, Inc. (NUVA) Company Bio

NuVasive develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company was founded in 1997 and is based in San Diego, California.

NUVA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$65.25$30.97 -56%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Nuvasive Inc. To summarize, we found that Nuvasive Inc ranked in the 33th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 56%. The most interesting components of our discounted cash flow analysis for Nuvasive Inc ended up being:

  • Nuvasive Inc's effective tax rate, as measured by taxes paid relative to net income, is at 108 -- greater than 97.89% of US stocks with positive free cash flow.
  • Nuvasive Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 0.02. This coverage rate is greater than that of only 23.09% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • The weighted average cost of capital for the company is 12. This value is greater than 85.85% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as NUVA, try DXCM, JNJ, IDXX, GMED, and NRC.

NUVA Latest News Stream

Event/Time News Detail
Loading, please wait...

NUVA Latest Social Stream

Loading social stream, please wait...

View Full NUVA Social Stream

Latest NUVA News From Around the Web

Below are the latest news stories about Nuvasive Inc that investors may wish to consider to help them evaluate NUVA as an investment opportunity.

Why Is NuVasive (NUVA) Down 5.2% Since Last Earnings Report?

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | June 4, 2021

Here's Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Looks Fair for the time being

Despite strong share price growth of 40% for NuVasive, Inc. ( NASDAQ:NUVA ) over the last few years, earnings growth...

Yahoo | May 12, 2021

NuVasive Appoints Juliet C. Cunningham as Vice President of Investor Relations

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the appointment of Juliet C. Cunningham as the vice president of Investor Relations, effective immediately. In this role, Ms. Cunningham is responsible for the Company's investor relations program and reports directly to Chief Financial Officer Matt Harbaugh.

Yahoo | May 10, 2021

Leerink Partners Stick to Their Buy Rating for Nuvasive By

Leerink Partners Stick to Their Buy Rating for Nuvasive | May 9, 2021

NuVasive (NUVA) Beats Q1 Earnings and Revenue Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of 12.12% and 3.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 5, 2021

Read More 'NUVA' Stories Here

NUVA Price Returns

1-mo -6.16%
3-mo -0.81%
6-mo 42.25%
1-year 12.50%
3-year 19.13%
5-year 12.35%
YTD 15.84%
2020 -27.17%
2019 56.05%
2018 -15.27%
2017 -13.17%
2016 24.49%

Continue Researching NUVA

Here are a few links from around the web to help you further your research on Nuvasive Inc's stock as an investment opportunity:

Nuvasive Inc (NUVA) Stock Price | Nasdaq
Nuvasive Inc (NUVA) Stock Quote, History and News - Yahoo Finance
Nuvasive Inc (NUVA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9598 seconds.